| Objective To systematically evaluate the current status of research on therapeutic drugs and genes in adult renal trans-plant recipients in China, and to summarise drug-related genes, so as to provide evidence-based medical references for the individuali-sation of drugs in clinical renal transplant recipients.Methods Computer searches of CNKI, VIP, Pubmed, Web of Science and Wan.fang databases were performed from the time of database construction to September 2024, and relevant literature involving therapeuticdrugs and genes in Chinese adult renal transplantation was included to analyse the correlation between the relevant genes and drug dos-age and concentration, co-administration of medications, pharmacokinetics, and adverse reactions, and descriptive analyses were per-formed on the results. The results were analysed descriptively.Results A total of 89 papers were included, published between 2008 and 2024, with a study sample of 35-845 cases and an age distribution of recipients between 18 and 79 years. The study found 22 genesrelated to blood concentration/drug dose, including CYP3A5, CYP3A4 and ABCB1; 7 genes related to pharmacokinetics, including CYP3A5, ABCB1, and UGT; and 11 genes related to adverse effects, including CYP3A5, CYP3A4 and ABCB1.Conclusions The ge-nomics of therapeutic drugs in Chinese adult kidney transplant patients is developing rapidly and involves a large number of genes, in-cluding 22 genes related to blood concentration/dosage, 7 genes related to pharmacokinetics, and 11 genes related to adverse effects,which can be used more scientifically by genotyping patients. In the future, more multi-center, large-sample, high-quality studies areneeded to further clarify the relationship between related genes and drug effects, and to improve drug efficacy and safety. |
